Activase manufacturing "interval"
Genentech is "maintaining adequate stocks of TPA to meet current demand and to respond to renewed growth in the market for thrombolytic, or clot-dissolving, therapy," the firm said in an Oct. 13 statement explaining its decision to halt production of the drug for the balance of 1988. Genentech said it manufacturers TPA "on a campaign basis" with "intervals scheduled between the manufacture of different products." Genentech's manufacturing plant during the first half of 1988 ran "at a rate considerably higher than matching sales" in order to allow the plant to be available for production of other cell-based products, including the CD4 potential AIDS therapy, the firm maintained. CD4 entered Phase I study in August.
You may also be interested in...
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.